Andrea L. Kasinski
Department of Biological Sciences,
Purdue Institute for Cancer Research
Purdue University
Andrea L. Kasinski has not added Biography.
If you are Andrea L. Kasinski and would like to personalize this page please email our Author Liaison for assistance.
Aberrant regulation and function of microRNAs in cancer.
Current biology : CB Aug, 2014 | Pubmed ID: 25137592
A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer.
Oncogene Jul, 2015 | Pubmed ID: 25174400
RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes.
Journal of hematology & oncology Apr, 2015 | Pubmed ID: 25888285
MicroRNAs in Cancer: A Historical Perspective on the Path from Discovery to Therapy.
Cancers Jul, 2015 | Pubmed ID: 26226002
Targeting adhesion signaling in mutant lung adenocarcinoma.
JCI insight Mar, 2017 | Pubmed ID: 28289710
Sulforhodamine B (SRB) Assay in Cell Culture to Investigate Cell Proliferation.
Bio-protocol Nov, 2016 | Pubmed ID: 28573164
FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer.
Science translational medicine Aug, 2017 | Pubmed ID: 28768807
Animal Models to Study MicroRNA Function.
Advances in cancer research , 2017 | Pubmed ID: 28882225
No vehicle, no problem.
Oncotarget Nov, 2017 | Pubmed ID: 29228541
MicroRNA-223 Suppresses the Canonical NF-κB Pathway in Basal Keratinocytes to Dampen Neutrophilic Inflammation.
Cell reports Feb, 2018 | Pubmed ID: 29444433
New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K/H Exchange.
Bioconjugate chemistry Apr, 2018 | Pubmed ID: 29446616
Enhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin.
Molecular therapy. Nucleic acids Jun, 2019 | Pubmed ID: 31071527
Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics.
Cell cycle (Georgetown, Tex.) Aug, 2019 | Pubmed ID: 31258013
Combatting PDAC with two tumor-targeting small RNAs.
Oncotarget Oct, 2019 | Pubmed ID: 31666921
Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer.
Biochemical pharmacology Jul, 2021 | Pubmed ID: 32681833
InVivo Cancer-Based Functional Genomics.
Trends in cancer Dec, 2020 | Pubmed ID: 32828714
MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic.
Frontiers in cell and developmental biology , 2021 | Pubmed ID: 33763422
Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases.
NAR cancer Sep, 2021 | Pubmed ID: 34316717
Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells.
Scientific reports Jan, 2022 | Pubmed ID: 35046472
Author Correction: Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells.
Scientific reports Feb, 2022 | Pubmed ID: 35165361
Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET.
Cancer research Apr, 2022 | Pubmed ID: 35404406
In-Cell Western Protocol for Semi-High-Throughput Screening of Single Clones.
Bio-protocol Aug, 2022 | Pubmed ID: 36199701
Emerging diversity in extracellular vesicles and their roles in cancer.
Frontiers in oncology , 2023 | Pubmed ID: 37397375
A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy.
Oncogene Sep, 2023 | Pubmed ID: 37666938
Histone 4 lysine 20 tri-methylation: a key epigenetic regulator in chromatin structure and disease.
Frontiers in genetics , 2023 | Pubmed ID: 37671044
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유